Keywords
SARS-CoV-2
Epidemiology
Respiratory Insufficiency
Pneumonia, Viral
How to Cite
Abstract
Introduction. Respiratory syncytial virus (RSV) is one of the main causes of respiratory infections in children, mainly those under two years of age. Furthermore, it´s considered a cause of death in children under one years of age. According to studies, the steps implemented during SARS-CoV-2 pandemic have had an impact in the epidemiology of hospitalizations for this infection. The objective is know the incidence and the characteristics of RSV hospitalizations in children of spanish province.
Methods. A retrospective descriptive study was conducted on hospital discharges of patients under 15 years of age belonging to a province over a period of 21 years.
Results. Of the 32,957 hospitalizations, 2.8% were diagnosed with RSV infection. 94.6% of hospitalizations were in the province where the patients in the study were located. The median stay was 4.22 days. The average age of hospitalization from 2001 to 2020 was between 5 and 9 months. However, in 2021 the average age of hospitalization was 13 months. There was a non-significant (p= 0.08) annual decline of 2% in the hospitalizations rate in the 21 years. There is a dominant circannual rhythm with acrophase on January 27 (p< 0.01). No deaths were recorded.
Conclusion. Change point haven´t been identified between 2001 and 2021, but have been observed marked seasonality with acrophase in January.
References
Colosia A, Costello J, McQuarrie K, Kato K, Bertzos K. Sys- tematic literature review of the signs and symptoms of res- piratory syncytial virus. Influenza Other Respir Viruses. 2023;17(2):e13100. https://doi.org/10.1111/irv.13100. https://doi.org/10.1111/irv.13100
Shi T, Ooi Y, Zaw EM, Utjesanovic N, Campbell H, Cunningham S, et al. Association between respiratory syncytial virus-associa- ted acute lower respiratory infection in early life and recurrent wheeze and asthma in later childhood. J Infect Dis. 2020;222 (Suppl 7):S628-33. https://doi.org/10.1093/infdis/jiz311. https://doi.org/10.1093/infdis/jiz311
Duan Y, Jiang M, Huang Q, Jia M, Yang W, Feng L. Incidence, hospitalization, and mortality in children aged 5 years and youn- ger with respiratory syncytial virus-related diseases: A systema- tic review and meta-analysis. Influenza Other Respir Viruses. 2023;17(5):e13145. https://doi.org/10.1111/irv.13145. https://doi.org/10.1111/irv.13145
Zhang S, Akmar LZ, Bailey F, Rath BA, Alchikh M, Schweiger B, et al. Cost of respiratory syncytial virus-associated acute lower respiratory infection management in young children at the regional and global level: A systematic review and meta- analysis. J Infect Dis. 2020;222(Suppl 7):S680-7. https://doi. org/10.1093/infdis/jiz683.
Hernández-Rivas L, Pedraz T, Calvo C, San Juan I, Mellado MJ, Robustillo A. Respiratory syncytial virus outbreak during the COVID-19 pandemic. How has it changed? Enferm Infecc Microbiol Clin (Engl Ed). 2023;41(6):352-5. https://doi. org/10.1016/j.eimce.2021.12.018. https://doi.org/10.1016/j.eimce.2021.12.018
eCIE9MC. Edición electrónica de la Clasificación Internacional de Enfermedades, Modificación Clínica. 9.ª Edición. [Internet]. eCIEMaps; [citado 02 mar 2024]. Disponible en: https://ecie- maps.mscbs.gob.es/ecieMaps/browser/index_9_mc.html.
CIE-10-ES. Clasificación Internacional de Enfermedades. 10.ª Edición. Edición 2024. [Internet]. eCIEMaps; [citado 02 mar 2024]. Disponible en: https://www.eciemaps.sanidad.gob.es/ browser/metabuscador.
Montejo M, Sánchez A, Paniagua N, Saiz-Hernando C, Benito, J. Reduction in the incidence of acute bronchiolitis and related hospital admissions during the COVID-19 pandemic. An Pediatr (Engl Ed). 2022;96(6):537-9. https://doi.org/10.1016/j.anpe- de.2022.03.003. https://doi.org/10.1016/j.anpede.2022.03.003
Alonso A, Andres JM, Garmendia JR, Diez I, Gil JM, Ardu- ra J. Bronchiolitis due to respiratory syncytial virus in hos- pitalized children: a study of seasonal rhythm. Acta Paedia- trica. 2007;96(5):731-5. https://doi.org/10.1111/j.1651- 2227.2007.00266.x.
https://doi.org/10.1111/j.1651-2227.2007.00266.x
Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Caba- ñas F, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180-9. https://doi.org/10.1016/S2352-4642(22)00321-2. https://doi.org/10.1016/S2352-4642(22)00321-2
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2026 Boletín de Pediatría